Coronavirus Update: FDA Tries To Control J&J’s Vaccine, Extended Use Of Paxlovid
The FDA has also moved to limit use of J&J’s COVID-19 vaccine amid reports of rare but dangerous blood clots, while Regeneron highlighted efforts to get approval for REGEN-COV in its Q1 earnings.
You may also be interested in...
A protein-based vaccine for COVID-19 reaches the US at last, but Novavax looks set miss out once again as the fall deadline for BA.4/5 variant-targeting vaccines approaches.
After 34 years of seeing and shaping Johnson & Johnson’s future, executive chair Alex Gorsky has recently joined Apple’s board of directors. At a recent event, he shared lessons for future leaders while unraveling some of the thinking behind decisions taken as chair and CEO
AstraZeneca also published efficacy data for Evusheld in patients with mild-to-moderate COVID-19, while Pfizer is investing $120m in expanding its Paxlovid manufacturing footprint in Michigan.